참고문헌
- Gonen Y, Jacobson W, Casper RF. Gonadotropin suppression with oral contraceptives before in vitro fertilization. Fertil Steril 1990; 53: 282-7. https://doi.org/10.1016/S0015-0282(16)53282-8
- Loutradis D, Drakakis P, Kallianidis K, Milingos S, Dendrinos S, Michalas S. Oocyte morphology correlates with embryo quality and pregnancy rate after intracytoplasmic sperm injection. Fertil Steril 1999; 72: 240-4. https://doi.org/10.1016/S0015-0282(99)00233-2
- choolcraft WB. Evaluation and treatment of the poor responder. Clin Obstet Gynecol 2006; 49: 23-33. https://doi.org/10.1097/01.grf.0000197265.94917.1e
- arci R, Caserta D, Dolo V, Tatone C, Pavan A, Moscarini M. GnRH antagonist in IVF poor-responder patients: results of a randomized trial. Reprod Biomed Online 2005; 11: 189-93. https://doi.org/10.1016/S1472-6483(10)60957-1
- Lin Y, Kahn JA, Hillensjo T. Is there a difference in the function of granulosa-luteal cells in patients undergoing invitro fertilization either with gonadotrophin-releasing hormone agonist or gonadotrophin-releasing hormone antagonist? Hum Reprod 1999; 14: 885-8. https://doi.org/10.1093/humrep/14.4.885
- Turhan NO. Poor response-the devil is in the definition. Fertil Steril 2006; 86: 777.
- hang MY, Chiang CH, Hsieh TT, Soong YK, Hsu KH. Use of the antral follicle count to predict the outcome of assisted reproductive technologies. Fertil Steril 1998; 69: 505-10. https://doi.org/10.1016/S0015-0282(97)00557-8
- Frattarelli JL, Bergh PA, Drews MR, Sharara FI, Scott RT. Evaluation of basal estradiol levels in assisted reproductive technology cycles. Fertil Steril 2000; 74: 518-24. https://doi.org/10.1016/S0015-0282(00)00693-2
- Seifer DB, Lambert-Messerlian G, Hogan JW, Gardiner AC, Blazar AS, Berk CA. Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. Fertil Steril 1997; 67: 110-4. https://doi.org/10.1016/S0015-0282(97)81865-1
- Seifer DB, Maclaughlin DT. Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance. Fertil Steril 2007; 88: 539-46. https://doi.org/10.1016/j.fertnstert.2007.02.014
- Syrop CH, Willhoite A, Van Voorhis BJ. Ovarian volume: a novel outcome predictor for assisted reproduction. Fertil Steril 1995; 64: 1167-71. https://doi.org/10.1016/S0015-0282(16)57979-5
- Toner JP, Philput CB, Jones GS, Muasher SJ. Basal folliclestimulating hormone level is a better predictor of in vitro fertilization performance than age. Fertil Steril 1991; 55: 784-91. https://doi.org/10.1016/S0015-0282(16)54249-6
- van Rooij IA, Broekmans FJ, te Velde ER, Fauser BC, Bancsi LF, de Jong FH, et al. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 2002; 17: 3065-71. https://doi.org/10.1093/humrep/17.12.3065
- European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 2001; 16: 644-51. https://doi.org/10.1093/humrep/16.4.644
- Borm G, Mannaerts B. Treatment with the gonadotrophinreleasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Hum Reprod 2000; 15: 1490-8. https://doi.org/10.1093/humrep/15.7.1490
- Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau L, et al. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril 2000; 73: 314-20. https://doi.org/10.1016/S0015-0282(99)00524-5